Ultomiris has become one of the most important treatments in the rare disease space because of its ability to reduce the burden of chronic infusion therapy while improving patient outcomes across paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG). As a long-acting C5 complement inhibitor, Ultomiris was developed as the direct successor to Soliris, offering dosing once every eight weeks instead of once every two weeks.
This extended dosing interval has altered the way patients and healthcare providers view treatment. Fewer infusions mean better convenience, less travel and hospital visits, and a better quality of life overall, which drives greater treatment adherence amongst patients managing lifelong conditions. Alexion, part of AstraZeneca, said it had switched more than 85% of PNH and aHUS patients in the U.S. who were previously on Soliris to Ultomiris by the fourth quarter of 2023 and cited a rapid rate of adoption in the U.S. healthcare system.
The U.S. Ultomiris Drug Market was valued at approximately USD 1.57 billion in 2024 and is projected to reach around USD 11.57 billion by 2032, driven by early FDA approvals, strong reimbursement support through Medicare and Medicaid, expanding pediatric indications, and rising demand for at-home, self-administered treatment. Globally, the Ultomiris Drug Market was valued at USD 3.88 billion in 2024 and is expected to reach USD 28.84 billion by 2032, expanding at a CAGR of 28.55% during the forecast period of 2025–2032.
Gain Actionable Intelligence on the Ultomiris Drug Market - Request a Sample Report
U.S. Ultomiris Drug Market Analysis
The United States maintains its dominant position in the Ultomiris market because of early FDA approvals, strong disease awareness, and a well-established rare disease treatment infrastructure. Ultomiris received early U.S. regulatory clearance across multiple indications, including PNH, aHUS, and gMG, giving American healthcare providers a head start on adoption and commercialization compared to other global markets.
A robust reimbursement framework has been identified as a key driver of Ultomiris uptake in the US healthcare system. Ultomiris is an orphan-designated biologic with a high cost of more than USD 500,000 per patient per year. However, it is reimbursed under Medicare, Medicaid and private insurance plans and is accessible to eligible patients.
The move to home-based care has further accelerated demand in the US market. The approval of a subcutaneous, self-administered version of Ultomiris will allow patients to inject the drug at home approximately every two months using an on-body injector, which reduces reliance on infusion centres, lowers administrative costs and expands access for patients in rural areas.
Top 4 Leading Companies in the Ultomiris Drug Market
1. Roche Holding AG
Roche is a large player in the rare disease and immunology space and competes in therapeutic areas that overlap with Ultomiris’ core indications. The company is still committed to investing in biologics research related to complement-mediated and autoimmune diseases therapeutics.
With a large pipeline and a global distribution network, Roche is a big competitor in shaping innovation and setting standards of care in the same diseases that Ultomiris targets.
2. Novartis AG
Novartis is a big fish in the relatively rarified pool of rare diseases and specialty biologics, and both companies are still working on drugs for complement-mediated disorders and autoimmune diseases similar to what Ultomiris can treat. The combination of the company's scale and commitment to R&D makes it a key force in this sector.
Courtesy of landscape Novartis's focus on increasing targeted therapies for underserved patient populations follows a more broad industry trend toward effective long-acting biologic medications.
3. Apellis Pharmaceuticals
Apellis Pharmaceuticals is a new challenger in the complement inhibitor field, with drugs in development for all the same ultra-rare diseases that Ultomiris targets, including PNH. Its existence creates ongoing competitive pressure that drives innovation in dosing convenience and efficacy of treatment.
Apellis, as a more niche biotech with its newfound focus on rare diseases, is poised to ride the same trend of increasingly targeted competition threatening bigger players in the pipeline for treating those disorders.
4. Argenx
Argenx sits well positioned in the autoimmune and rare disease market, with a particular connection to generalized myasthenia gravis, an indication where Ultomiris is one of the faster growing indications. That focus on therapies based on antibodies makes this company one of the most serious competitors in that exact class of disease.
This expansion of Argenx into gMG fits with a larger trend in which specialized biotech companies are increasingly entering fields of great need together with the larger, established pharmaceutical players.
What the Future of the Ultomiris Drug Market Holds
Continued clinical advancement, therapy broadening into new areas and greater access to treatment will shape the future of the Ultomiris market. Continued research to optimize efficacy, safety and durability is expected to further drive long-term use and integration in more behaviours of these various diseases that Ultomiris treats.
Digital platforms and healthcare advocacy efforts are raising awareness regarding Ultomiris as treatment option in newer settings, however the development of innovative formulations and delivery mechanisms is expanding its usage in non-rare disease indications. The availability of treatment in the U.S. healthcare system is also expected to broaden through strategic alliances, distribution networks and patient-assistance programs.
North America already represents 47.82% of global Ultomiris revenues in 2024, supported by early regulatory approvals, high disease awareness and a wide-ranging reimbursement landscape; the US alone is set to be the main growth engine for this entire market through 2032+ by some distance.
